Aridis Pharmaceuticals, Inc. Quarterly Debt-to-equity in % from Q3 2021 to Q3 2023

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Aridis Pharmaceuticals, Inc. quarterly Debt-to-equity history and growth rate from Q3 2021 to Q3 2023.
  • Aridis Pharmaceuticals, Inc. Debt-to-equity for the quarter ending September 30, 2023 was -147 %, a 16% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q3 2023 -147 +28 +16% Sep 30, 2023
Q2 2023 -139 +98.5 +41.5% Jun 30, 2023
Q1 2023 -141 +130 +48% Mar 31, 2023
Q4 2022 -156 +152 +49.3% Dec 31, 2022
Q3 2022 -175 +126 +41.9% Sep 30, 2022
Q2 2022 -237 Jun 30, 2022
Q1 2022 -271 Mar 31, 2022
Q4 2021 -308 Dec 31, 2021
Q3 2021 -301 Sep 30, 2021
* An asterisk sign (*) next to the value indicates that the value is likely invalid.